|Dr. Gérard Soula M.B.A., Ph.D.||Co-Founder & Chairman||370.62k||N/A||1945|
|Mr. Olivier Soula M.B.A., Ph.D.||Co-Founder, CEO & Director||278.63k||N/A||1970|
|Ms. Valérie Danaguezian||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Geraldine Favre Soula||HR Devel. Director||N/A||N/A||N/A|
|Dr. Bertrand Alluis||Head of the Analysis Department and Project Mang.||N/A||N/A||N/A|
|Dr. David Duracher||Head of the Pharmaceutical Devel. & Physical Chemistry Departments and Project Mang.||N/A||N/A||N/A|
|Dr. Richard Charvet||Head of Chemistry Department & Project Mang.||N/A||N/A||N/A|
|Dr. Grégory Meiffren||Head of the Biology Department & Project Mang.||N/A||N/A||N/A|
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Adocia SA’s ISS Governance QualityScore as of September 1, 2023 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 9; Compensation: 10.